Celgene's slide continues after refusal to file letter

Celgene Corp. (NASDAQ:CELG) shed $8.66 to $87.12 on Wednesday after FDA issued a refusal to file letter for an NDA for ozanimod (RPC1063)

Read the full 239 word article

User Sign In